Todd Green

VP Clin Dev & Med Affairs, DBV Technologies; Clin Assoc Prof, UPMC Children’s Hospital of Pittsburgh. Postings & opinions are my own and not DBV’s or UPMC’s.

[DBV Technologies @DBVTechnologies]

We are excited to have our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in children 1-3 years published in The New England Journal of Medicine (@NEJM ). Watch below and read the publication here: https://t.co/y5v4oX2K8A

[NEJM @NEJM]

In the phase 3 EPITOPE trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy by means of a peanut patch was superior to placebo in desensitizing children to peanut. https://t.co/USk6HBI9Qh

#pediatrics

[Dr. Dave Stukus @AllergyKidsDoc]

We’ve seen promising safety and efficacy data for the peanut patch in children and adolescents…

Great to see similar benefit in toddlers as well!

Hot off the press: https://t.co/x9JeUjwAoB

[DBV Technologies @DBVTechnologies]

We're proud to share that @NEJM has published our EPITOPE Phase 3 trial evaluating our investigational Viaskin Peanut in #PeanutAllergic children 1-3 years. Learn more here: https://t.co/HlGjDG5q0q

[DBV Technologies @DBVTechnologies]

We are pleased to announce FDA provided pre-BLA written response on regulatory path for Viaskin Peanut patch in 1-3 year olds with confirmed peanut allergy. Read more here: https://t.co/oTf5hcCEzP

[DBV Technologies @DBVTechnologies]

We are excited to announce the first patient screened in our VITESSE Phase 3 clinical trial in #PeanutAllergic children 4-7 years old. Read more about our trial here: https://t.co/L6fWg6OZK1

[Brian Vickery @ATLergist]

Looking forward to launching this trial soon at @EmoryPediatrics & @childrensatl @AtlPedsResearch! ATL families with peanut allergic kids aged 4-7, take note:

[Kevin Pho, M.D. @kevinmd]

Food allergy tragedies: the reality that haunts us https://t.co/SF0yH27p6Y #Conditions #AllergiesImmunology via @kevinmd

[George du Toit @GoAllergy]

Gideon Lack and @jandrewbird talking to early peanut introduction for peanut allergy prevention - #ACAAI22

[Todd Green @TGAllergy]

Couldn’t agree more- congratulations, Geoff!

[Todd Green @TGAllergy]

Agree!
@ACAAI @AllergyKidsDoc

[Dr. Dave Stukus @AllergyKidsDoc]

The one and only Dr. Cox (aka @JohnCMcGinley 😆) does a great job in this video discussing how and why allergists can help👏

Love the awareness campaign by @ACAAI

https://t.co/CTw3LfPRFz

[Mary McHenry MD @maryjmchenry]

Dr Greenhawt reviews emerging research on treatment of peanut allergy #NAPAAC22

[Todd Green @TGAllergy]

@IFPIES

[Dr. Douglas Mack @DrDougMackMD]

#napaac22 @nowak_wegrzyn FPIES just this year had NIAID FPIES workshop - first ever!

[JACI In Practice @JACIInPractice]

In Press! The Impact of #Allergy #Specialty #Care on #Healthcare #Utilization #Among #Peanut #Allergy #Children in the #United #States https://t.co/hjHeKSDzuH

[AAAAI @AAAAI_org]

A new study in @JACIInPractice shows patients with #PeanutAllergy who receive care from an allergist experience significantly lower total mean costs than those who do not see a specialist.
https://t.co/tEEdux7N5g

[Todd Green @TGAllergy]

Glad to be a part of this study demonstrating the value of allergist/immunologist care @JACIInPractice @AAAAI_org @ACAAI @wheezemd

[Healio Allergy and Asthma @HealioAllergy]

Despite greater severity of disease, patients with peanut #allergy experience lower total mean health care costs than those with other food allergies, said researchers at @ChildrensColo. Also, @ruchisgupta of @cfaarnu shares her perspective. #foodallergy
https://t.co/WPSVGHhhDO

[Healio Allergy and Asthma @HealioAllergy]

Despite greater severity of disease, patients with peanut #allergy experience lower total mean health care costs than those with other food allergies, said researchers at @ChildrensColo. Also, @ruchisgupta of @cfaarnu shares her perspective. #foodallergy
https://t.co/WPSVGHhhDO

[Healio Allergy and Asthma @HealioAllergy]

Patients with peanut #allergy who receive care from an allergist experience significantly lower total mean costs than those who do not see a specialist, said researchers at @ChildrensColo. Also, @ruchisgupta of @NUFeinbergMed shares her perspective.
https://t.co/WPSVGGZ8pG

[JACI In Practice @JACIInPractice]

Read results from the Phase 3 REALISE trial studying the safety and tolerability of epicutaneous immunotherapy with investigational patch treatment in children, supporting its continued investigation as a new potential treatment option for peanut allergy. https://t.co/60bpA7Ikog

[Medscape @Medscape]

Why in-flight emergency kits need an update https://t.co/tpCJkyt5Ts